We are analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you could provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:
• Abatacept [Orencia]
• Adalimumab [Humira]
• Adalimumab Biosimilars
• Apremilast [Otezla]
• Baricitinib [Olumiant]
• Certolizumab [Cimzia]
• Etanercept [Enbrel]
• Etanercept Biosimilars
• Filgotinib [Jyseleca]
• Golimumab [Simponi]
• Guselkumab [Tremfya]
• Infliximab [Remicade]
• Infliximab Biosimilars
• Ixekizumab [Taltz]
• Risankizumab [Skyrizi]
• Rituximab [MabThera]
• Rituximab Biosimilars
• Sarilumab [Kevzara]
• Secukinumab [Cosentyx]
• Tocilizumab [Ro Actemra]
• Tofacitinib [Xeljanz]
• Upadacitinib [Rinvoq]
• Ustekinumab [Stelara]
